News

Zhittya Genesis Medicine is hosting a webinar next week to provide information about the recently announced “Compassionate Use Clinical Trial” of the company’s lead therapy for Parkinson’s disease. The webinar is taking place on Tuesday, Feb. 1, at 3 p.m. Pacific time (6 p.m. Eastern). Registration is…

Lundbeck, with support from the Michael J. Fox Foundation (MJFF), is working to develop a “state of the art” biomarker test that could diagnose neurodegenerative diseases like Parkinson’s in early stages. The test, or assay, being developed in collaboration with scientists at the Danish Technical University (DTU) may also…

An international team of scientists is calling for more research about how to better care for women with Parkinson’s disease (PD). “Given the millions of women affected worldwide with PD, and the known differences in this disease’s manifestations and effects between genders, remarkably very little has been done to…

The Scottish Medicines Consortium (SMC) has added Ongentys (opicapone) — an add-on oral therapy to levodopa/Dopa decarboxylase inhibitors regimens (such as carbidopa) — to the list of medications available through the country’s National Health Service (NHS) to Parkinson’s patients experiencing ‘off’ periods. The decision comes more than five…

The Parkinson’s and Movement Disorder Center at the Queen’s Medical Center will use a $387,000 Michael J. Fox Foundation (MJFF) grant to study disparities in Parkinson’s disease care among Asian Americans, native Hawaiians, and Pacific Islanders, and to identify better approaches. The project is titled “Disparities in Care of…

L-dopa or levodopa, a standard treatment for Parkinson’s disease, forms a stable complex with iron and siderocalin, a protein involved in iron uptake by cells and found at higher levels in a brain region largely affected by Parkinson’s, a study shows. These early findings suggest that the formation…

The first patient has been treated in BioVie’s Phase 2 clinical trial assessing the impact of its investigational therapy, NE3107, on the motor symptoms of Parkinson’s disease. Study results for the Phase 2 trial, known as NM201, are expected by the end of 2022. “Enrollment of the first…

A new training program, the Bachmann-Strauss Fellowship in Dystonia Research aims to grow the number of researchers focused on the movement disorder known as dystonia. Launched by the Michael J. Fox Foundation for Parkinson’s Research (MJFF), the fellowship will support specialized training for those dedicated to investigating the causes…

Regular and sustained physical activity, including daily pursuits such as walking or gardening, may help slow the progression of Parkinson’s in people with early-stage disease, a long-term follow-up study suggests. Patients who exercised regularly over five years showed better motor and cognitive outcomes. “Our results are exciting, because they suggest it…

A first patient in Canada has been dosed in a Phase 1 clinical trial of DA01, a cell-based investigational therapy for advanced Parkinson’s disease by BlueRock Therapeutics. The therapy consists of surgically injecting neurons (nerve cells) that make dopamine — and which are damaged and die with Parkinson’s — into…